We are advancing cannabinoid science from category to care by building the regulated systems, scientific rigor, and clinical infrastructure required for legitimacy in medicine. The transition of cannabinoids from informal markets into medicine requires pharmaceutical discipline, regulatory clarity, and system-level accountability. Without these foundations, innovation cannot translate into healthcare. Kazmira was built to operate that transition — establishing the systems required for cannabinoids to be evaluated, governed, and deployed within healthcare standards.